BioSpace News Archive

Advaxis, Inc. announced that it is increasing its focus on neoantigen-directed immunotherapies and closing the AIM2CERV Phase 3 clinical trial with axalimogene filolisbac in high-risk locally advanced cervical cancer.

Acerus Pharmaceuticals Corporation announced that Health Canada has completed the initial screening process for the previously announced New Drug Submission for avanafil.

On June 27, 2019, the global leading chemical company BOC Sciences announced to establish a medicinal chemistry branch, which is specially designed to support scientists’ needs arising from drug discovery efforts, covering nearly the whole process of a drug discovery project from lead discovery all the way to formulation issues.

Allen Technologies and its E3 Patient Engagement Solution is helping to impact impressive improvements in hospital patient satisfaction and value-based incentive payments, according to CMS data for Northern Westchester Hospital (NWH) in upstate New York.

Publicis Health Media (PHM) today announced one new judge addition to its inaugural HealthFront event, taking place July 16-17 at the Classic Car Club Manhattan.

Halo Communications is pleased to announce its Gatekeeper functionality for the Halo Clinical Communication Platform™

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food and Drug Administration (FDA) approved SOLIRIS® (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.1

Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that it has become apparent that the Company will not be in a position to publish its audited financial statements for the year ended December 2018 (“2018 Accounts”) by 30 June 2019, in accordance with the AIM Rules for Companies.

According to Technavio Research Report “Medical Marijuana Market by application (chronic pain, nausea and others) and geography (the Americas, APAC and EMEA) is witnessed to grow USD 25.25 billion, at a CAGR of 21% from 2018 to 2022”.

Families asked, leadership responded by providing virtual access to infants hospitalized in NICU